Summary of the Fourth Annual American Sexually Transmitted Diseases Association Workshop on Improving Sexually Transmitted Infection Control Efforts Through Cross-Sector Collaboration.
Journal
Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
pubmed:
25
5
2022
medline:
15
7
2022
entrez:
24
5
2022
Statut:
ppublish
Résumé
The American Sexually Transmitted Diseases Association has, for several years, been conducting a cross-sector workshop to bring together a variety of stakeholders to develop ideas for collaboratively improving the sexually transmitted infection control efforts in the United States. In this summary, we share the content of discussions and ideas of the fourth annual workshop for future research and potential changes to practice with a focus on diagnostic capacity.
Identifiants
pubmed: 35608091
doi: 10.1097/OLQ.0000000000001651
pii: 00007435-202208000-00011
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
588-593Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Sexually Transmitted Diseases Association.
Déclaration de conflit d'intérêts
Conflict of Interest and Sources of Funding: Funding support for the workshop was received by ASTDA from Abbott Molecular, BD Diagnostics, BioFire Diagnostics, Hologic, Quest Diagnostics Nichols Institute, Roche Molecular, and SpeeDx. Authors from several of those entities contributed to the preparation of this manuscript. All other authors declare no conflict of interests.
Références
Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2019. Atlanta, GA: U.S. Department of Health and Human Services, 2021.
Wi TE, Ndowa FJ, Ferreyra C, et al. Diagnosing sexually transmitted infections in resource-constrained settings: Challenges and ways forward. J Int AIDS Soc 2019; 22(Suppl 6):e25343.
U.S. Department of Health and Human Services. Sexually Transmitted Infections National Strategic Plan for the United States: 2021–2025. Washington, DC: U.S. Department of Health and Human Services, 2020.
National Academies of Sciences, Engineering, and Medicine. Sexually Transmitted Infections: Adopting a Sexual Health Paradigm. Washington, DC: The National Academies Press, 2021.
Rietmeijer CA, Kissinger PJ, Guilamo-Ramos V, et al. Report from the National Academies of Sciences, Engineering and Medicine-STI: Adopting a sexual health paradigm—a synopsis for sexually transmitted infection practitioners, clinicians, and researchers. Sex Transm Dis 2021; 49:169–175.
Ronn MM, Menzies NA, Gift TL, et al. Potential for point-of-care tests to reduce chlamydia-associated burden in the United States: A mathematical modeling analysis. Clin Infect Dis 2020; 70:1816–1823.
Tucker JD, Bien CH, Peeling RW. Point-of-care testing for sexually transmitted infections: Recent advances and implications for disease control. Curr Opin Infect Dis 2013; 26:73–79.
Gettinger J, Van Wagoner N, Daniels B, et al. Patients are willing to wait for rapid sexually transmitted infection results in a university student health clinic. Sex Transm Dis 2020; 47:67–69.
Harding-Esch EM, Nori AV, Hegazi A, et al. Impact of deploying multiple point-of-care tests with a 'sample first' approach on a sexual health clinical care pathway. A service evaluation. Sex Transm Infect 2017; 93:424–429.
Drain PK, Dorward J, Bender A, et al. Point-of-care HIV viral load testing: An essential tool for a sustainable Global HIV/AIDS response. Clin Microbiol Rev 2019; 32:e00097–e00018.
Gaydos CA, Melendez JH. Point-by-point progress: Gonorrhea point of care tests. Expert Rev Mol Diagn 2020; 20:803–813.
Barbosa W, Zhou K, Waddell E, et al. Improving access to care: Telemedicine across medical domains. Annu Rev Public Health 2021; 42:463–481.
Kichloo A, Albosta M, Dettloff K, et al. Telemedicine, the current COVID-19 pandemic and the future: A narrative review and perspectives moving forward in the USA. Fam Med Community Health 2020; 8:e000530.
Ortega G, Rodriguez JA, Maurer LR, et al. Telemedicine, COVID-19, and disparities: Policy implications. Health Policy Technol 2020; 9:368–371.
Barbee LA, Dhanireddy S, Tat SA, et al. Barriers to bacterial sexually transmitted infection testing of HIV-infected men who have sex with men engaged in HIV primary care. Sex Transm Dis 2015; 42:590–594.
Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep 2021; 70:1–187.
Exten C, Pinto CN, Gaynor AM, et al. Direct-to-consumer sexually transmitted infection testing services: A position statement from the American Sexually Transmitted Diseases Association. Sex Transm Dis 2021; 48:e155–e159.
Morris SR, Bristow CC, Wierzbicki MR, et al. Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis : A cross-sectional study. Lancet Infect Dis 2021; 21:668–676.
St Cyr S, Barbee L, Workowski KA, et al. Update to CDC's treatment guidelines for gonococcal infection, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1911–1916.
Allan-Blitz LT, Humphries RM, Hemarajata P, et al. Implementation of a rapid genotypic assay to promote targeted ciprofloxacin therapy of Neisseria gonorrhoeae in a large health system. Clin Infect Dis 2017; 64:1268–1270.
Eyre DW, De Silva D, Cole K, et al. WGS to predict antibiotic MICs for Neisseria gonorrhoeae . J Antimicrob Chemother 2017; 72:1937–1947.
Donà V, Low N, Golparian D, et al. Recent advances in the development and use of molecular tests to predict antimicrobial resistance in Neisseria gonorrhoeae . Expert Rev Mol Diagn 2017; 17:845–859.
Lin EY, Adamson PC, Deng X, et al. Establishing novel molecular algorithms to predict decreased susceptibility to ceftriaxone in Neisseria gonorrhoeae strains. J Infect Dis 2021; 223:1232–1240.
Hashemi MM, Ram-Mohan N, Yang X, et al. A novel platform using RNA signatures to accelerate antimicrobial susceptibility testing in Neisseria gonorrhoeae . J Clin Microbiol 2020; 58:e01152–e01120.
Wadsworth CB, Sater MRA, Bhattacharyya RP, et al. Impact of species diversity on the design of RNA-based diagnostics for antibiotic resistance in Neisseria gonorrhoeae . Antimicrob Agents Chemother 2019; 63:e00549–e00519.
Gnanadurai R, Fifer H. Mycoplasma genitalium : A review. Microbiology (Reading) 2020; 166:21–29.
Jensen JS, Bradshaw C. Management of Mycoplasma genitalium infections—Can we hit a moving target?BMC Infect Dis 2015; 15:343.
Machalek DA, Tao Y, Shilling H, et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium : A systematic review and meta-analysis. Lancet Infect Dis 2020; 20:1302–1314.
Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: Centers for Disease Control and Prevention, 2019.
Dukers-Muijrers NH, Morré SA, Speksnijder A, et al. Chlamydia trachomatis test-of-cure cannot be based on a single highly sensitive laboratory test taken at least 3 weeks after treatment. PLoS One 2012; 7:e34108.